Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers

28 Jan 2021

Abstract excerpt

Abstract Effective treatment of pediatric solid tumors has been hampered by the predominance of currently “undruggable” driver transcription factors. Improving outcomes while decreasing the toxicity of treatment necessitates the development of novel agents that can directly inhibit or degrade these elusive targets. MYCN in pediatric neural-derived tumors, including neuroblastoma and medulloblastoma, is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neuroblastoma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33509943
DOI: 10.1158/0008-5472.can-20-3108

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood CancersPMID 33509943Read ↗

Targeting MYCN in Molecularly Defined Malignant Brain TumorsSemantic proximity Read ↗

MYCN as an oncogene in pediatric brain tumorsSemantic proximity Read ↗

Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges AheadSemantic proximity Read ↗

Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding InterfaceSemantic proximity Read ↗

Targeting MYC Proteins for Tumor TherapySemantic proximity Read ↗

Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-MycSemantic proximity Read ↗

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsSemantic proximity Read ↗

MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer AmplificationSemantic proximity Read ↗

Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor CellsSemantic proximity Read ↗

Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapiesSemantic proximity Read ↗

Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic InterventionSemantic proximity Read ↗

The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic PotentialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.